TNFRSF4 and neoplasm: For instance, in a phase Ib clinical trial (NCT02274155), neoadjuvant anti-OX40 (MEDI6469) therapy in patients with HNSCCs led to the activation and expansion of antigen-specific tumour-infiltrating T cells [496,497].